[CAS NO. 2622-26-6] Pericyazine
PRODUCTS SPECIFICATIONS [2622-26-6]
DESCRIPTION [2622-26-6]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 365.49 |
| Molecular Formula | C21H23N3OS |
| SMILES | N#CC(C=C1N2CCCN3CCC(O)CC3)=CC=C1SC4=C2C=CC=C4 |
Summary
Pericyazine (Propericiazine) is a first-generation antipsychotic agent that is used as an adjunct to the short-term management of severe anxiety states and psychosis [1] . Pericyazine is a selective D2-dopamine receptor antagonist [2] [3] . Pericyazine has adrenolytic, anticholinergic, and extrapyramidal effects [4] .
IC50 & Target
D2-dopamine receptor [2]
In Vivo
Studies in rodents show that Pericyazine is able to produce potentiation of ether and hexobarbital narcosis and morphine analgesia. It also has hypothermic activity and produces depression of spontaneous motor activity in mice. On a milligram potency basis, Pericyazine is more potent than chlorpromizine in the potentiation of barbiturate narcosis test and the blocking of conditioned avoidance in rats. Pericyazine demonstrates analgesic properties similar to methotrimeprazine in mice and rats and produces adrenergic blocking effects in mice and dogs [4] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 250 mg/mL ( 684.01 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.7361 mL | 13.6803 mL | 27.3605 mL |
| 5 mM | 0.5472 mL | 2.7361 mL | 5.4721 mL |
| 10 mM | 0.2736 mL | 1.3680 mL | 2.7361 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (5.69 mM); Clear solution
References
- [1] Morley KC, et al. Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial. Subst Abuse Rehabil. 2012 May 28;3:43-7.
- [2] Farde L, et al. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypicalneuroleptics. Psychopharmacology (Berl). 1989;99 Suppl:S28-31.
- [3] Divac N, et al. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370.
- [4] Cai HL, et al. A sensitive LC-MS/MS method for analysis of pericyazine in presence of 7-hydroxypericyazine and pericyazine sulphoxide in human plasma and its application to a comparative bioequivalence study in Chinese healthy volunteers. J Pharm Biomed A
Synonyms
